Want to see OABI full AI Analyst Report?
OABI Stock Chart & Stats
$4.47
-$0.01(-0.51%)
At close: 4:00 PM EDT
$4.47
-$0.01(-0.51%)
Day’s Range― - ―
52-Week Range$1.30 - $5.43
Previous CloseN/A
Volume186.59K
Average Volume (3M)1.44M
Market Cap
$693.51M
Enterprise Value$283.75M
Total Cash (Recent Filing)$51.99M
Total Debt (Recent Filing)$18.91M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 17, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding145,390,400
10 Day Avg. Volume1,489,067
30 Day Avg. Volume1,437,411
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.79
Price to Sales (P/S)11.26
P/FCF Ratio-5.68
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue7.38
Enterprise Value/Gross Profit14.61
Enterprise Value/Ebitda-14.17
Forecast
1Y Price Target
$9.25Price Target Upside106.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$35.09M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRapid revenue growth and upgraded guidance indicate stronger monetization of OmniAb’s platform and partner activity. If sustained, the higher revenue base can improve operating leverage, support reinvestment in discovery technologies, and strengthen the company’s ability to convert programs into future milestones and royalties.
Partner Network And Contracted EconomicsA broad partner and program base diversifies development exposure and creates multiple routes to future milestone and royalty income. The high proportion of programs with contracted downstream economics provides durable economic participation beyond initial discovery and service revenue, supporting longer-term scalability.
Low Financial LeverageVery low leverage reduces interest and refinancing pressure while preserving financial flexibility during biotechnology development cycles. A balance sheet funded primarily by equity gives OmniAb more capacity to absorb operating volatility and allocate resources toward platform development and partner programs.
Bears Say
Persistent Losses And Cash BurnOmniAb is not yet funding operations through internally generated cash, and persistent losses indicate that the cost base remains well above current revenue scale. Continued burn can reduce financial flexibility over time and makes progress toward sustainable profitability dependent on growth, milestones, or additional funding.
Milestone Revenue VariabilityRevenue tied to development milestones can produce uneven results because partner achievements occur at uncertain times. Front-loaded milestones may make later-period comparisons and planning more difficult, reducing earnings visibility and complicating the company’s ability to match spending with recurring revenue.
Dependence On Partner DevelopmentOmniAb’s economics depend substantially on partners advancing programs through clinical and commercial stages, decisions outside its direct control. Delays, failures, or attrition could postpone milestones and royalties, leaving near-term revenue exposed despite the breadth of the program portfolio.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.30 and its highest was $5.43 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $693.51M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Nov 17, 2026 which is in 33 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Aug 06, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.07.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.13.
How many shares outstanding does OmniAb have?
OmniAb has 145,390,400 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went up 37.5%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OmniAb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (106.94% Upside)
$9.25 (106.94% Upside)
Blogger Sentiment
Bearish
OABI Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 180.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.1%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.12%
12-Months-Change
Fundamentals
Return on Equity
-16.59%
Trailing 12-Months
Asset Growth
-1.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OmniAb
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial year-over-year revenue growth (~244% for Q2 and ~243% YTD), marked improvement in net losses (~60%+ reduction), upgraded full-year revenue and cash guidance, expanding partner/program base, and notable clinical progression including two programs advancing rapidly to Phase III. Risks highlighted include the lumpiness of milestone-driven revenue, an early-stage xPloration commercialization ramp, ongoing (though reduced) GAAP losses, and dependence on partner development timelines for future royalties. On balance, positive execution and meaningful clinical/contracted upside appear to outweigh the near-term variability and commercialization risks.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$9.25
▲(106.94% Upside)
Technical Analysis
Ownership Overview
5.85% Insiders
9.87% Mutual Funds
0.04% Other Institutional Investors
75.27% Public Companies and
Individual Investors